Congruence for RAS/BRAF/PIK3CA was usually seen between cases analysed by clinical routine and with the Oncomine/WGS platforms but differed for 31 cases (5%), the choice of another sample with lower tumour cell count, or methodological issues, are possible reasons. This evidence concerns the gene PIK3CA and neoplasm.